First Manhattan’s Akero Therapeutics AKRO Stock Holding History

First Manhattan’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-150	Closed	-$7K	–	1491
2023 Q2	$7K	Hold	150	–	–	﹤0.01%	1189
2023 Q1	$5.74K	Hold	150	–	–	﹤0.01%	1280
2022 Q4	$8.22K	Hold	150	–	–	﹤0.01%	1295
2022 Q3	$5K	Hold	150	–	–	﹤0.01%	1299
2022 Q2	$1K	Hold	150	–	–	﹤0.01%	1461
2022 Q1	$2K	Hold	150	–	–	﹤0.01%	1474
2021 Q4	$3K	Hold	150	–	–	﹤0.01%	1435
2021 Q3	$3K	Hold	150	–	–	﹤0.01%	1473
2021 Q2	$3K	Hold	150	–	–	﹤0.01%	1464
2021 Q1	$4K	Buy	+150	New	+$4.54K	﹤0.01%	1363

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

First Manhattan's AKRO Position: Q3 2023 in Review

First Manhattan sold out of Akero Therapeutics (AKRO) in Q3 2023, closing a stake of 150 shares — an estimated $7K sold.

First Manhattan first reported a position in AKRO in Q1 2021 and held it in 10 quarters. The position peaked at $8.22K in Q4 2022. 181 funds tracked by Wall St. Rank hold AKRO as of Q3 2023.

First Manhattan reported no remaining Akero Therapeutics position as of Q3 2023 after selling out during the quarter.
First Manhattan sold 150 Akero Therapeutics shares in Q3 2023, an estimated $7K.
First Manhattan first reported a position in Akero Therapeutics in Q1 2021 and held it in 10 quarters.
First Manhattan's Akero Therapeutics position peaked at $8.22K in Q4 2022.
181 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2023.

Based on First Manhattan's 13F filing for Q3 2023, filed 14 Nov 2023.